Scintigraphy with -MIBI in the assessment and the prediction of multidrug resistance in patients with lymphoma
Main Article Content
Abstract
To determine the utility of scintigraphy with -MIBI for non-invasively assessment and prediction of multidrug resistance in patients with lymphoma. 152 patients were evaluated (120 with lymphoma and 32 with benign diseases of the lymph nodes). The biopsy of lymph nodes constituted the gold standard. Static images of thorax, abdomen and pelvis were acquired at 20 min, 2h, 3h and 4h after the intravenous administration of 925-1110 MBq (20-30 mCi) of -MIBI. The uptake indexes were determined for each time and the index of maximum uptake (ICmax) of the radiopharmaceutical for all patients was also calculated. The index of maximum uptake was compared with the clinical and hematological response to chemotherapy. The studies with -MIBI showed values of sensibility, specificity and diagnostic accuracy of 96%, 75% and 92%, respectively. Once chemotherapeutic treatment was concluded, 48 of the 120 studied patients with lymphoma showed complete remission of the disease, meanwhile 32 of them showed partial remission and non response to chemotherapy was observed in 40 cases. The outcomes of the present work revealed that a high index of maximum uptake (ICmax ³6) could be an indicator of good response to chemotherapy, values of ICmax in a range from 3 to 6 were associated to either complete or partial remission and a ICmax £3 could be an indicator of poor response to chemotherapy. The scintigraphy with -MIBI was a useful tool for the study of patients with lymphoma and the assessment of their response to chemotherapy.
Article Details
How to Cite
Peña Quian, Y., Perera Pintado, A., Batista Cuellar, J. F., & Hernández Ramírez, P. (1). Scintigraphy with -MIBI in the assessment and the prediction of multidrug resistance in patients with lymphoma. Nucleus, (41). Retrieved from http://nucleus.cubaenergia.cu/index.php/nucleus/article/view/487
Issue
Section
Ciencias Nucleares
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista. Bajo esta licencia el autor será libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
- El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia
Bajo las siguientes condiciones:
- Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
La Revista Nucleus solo aceptará contribuciones que no hayan sido previamente publicados y/o procesados, por otra publicación. Cualquier violación ese sentido será considerada una falta grave por parte del autor principal lo cual será objeto valoración por parte del Consejo Editorial, el cual dictaminará al respecto.
References
1. The World Health Organization Report 2005. World Health Organization. 2005.
2. PAREDES A, BLANCO C, ECHENIQUE M. Expresión de proteínas relacionadas con resistencia a múltiples drogas (MDR-Proteínas) en el cáncer de pulmón. Oncología. 2005; 28 ( 8): 378-393.
3. BAE KT, PIWNICA WORMS D. Pharmacokinetics modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates. Q J Nucl Med. 1997;( 41): 101-108.
4. CHIU M, KRONAUGE J, PIWNICA-WORMS D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxy-isobutyl-isonitrile) technetium I in cultured mouse fibroblasts. J Nucl Med. 1990;( 31): 1646-1653.
5. OZLEM KL, AKYUZ C, VURAL G, OGUZ A, ATASEUER T. BUYUKPAMUKCU, Evaluation of therapy response in children with untreated malignant lymphomas using Tc-99m-sestamibi. J Nucl Med. 1997;( 38): 243-247.
6. PROULX A, BALLINGER JR, GULENCHYN KY. Routine determination of radiochemical purity of (99m)Tc-MIBI. Appl Radiat Isot. 1989;( 40): 95-97.
7. LEE NS, JAFFE E, STEIN H, BANKS P, CHAN J, CLEARY M, et al. A revised European-American classification of lymphoid neoplasm: A proposal from the international lymphoma study group. Blood. 1994;( 84): 1361-1392.
8. KOMOTO D, NISHIYAMA Y, YAMAMOTO Y, MONDEN T, SASAKAWA Y, TOYAMA Y, SATOH K, OHNO M, KANENISHI K, OHKAWAM. A case of non-hodgkin’s lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response. Ann Nucl Med. 2006; 20 ( 2): 157-160.
9. ZIJLSTRA JM, LINDAUER-VAN-DER-WERF G, HOEKSTRA OS, HOOFT L, RIPHAGEN II, HUIJGENS PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica. 2006; 91 ( 4): 522-529.
10. RICART Y. La gammagrafía con citrato de 67Ga en el estudio de los linfomas. Rev Esp Med Nuclear. 2002;( 21): 85-87.
11. LIN PC, CHUN J, POCOCK N. 18F Fluorodeoxyglucose imaging with coincidence dual-head gamma camera (hybrid-PET) for staging of lymphoma: comparison with Ga-67 scintigraphy. J Nucl Med. 2000;( 41) (suppl): 118.
12. SOLANO BRAVO ME, PERERA PINTADO A, GÓMEZ PÉREZ JR, RODRÍGUEZ JL, SÁNCHEZ MENDOZA EL, PÉREZ VALDÉS M, SÁNCHEZ-DEL-CAMPO-ROMERO MP. Valor de la gammagrafía con 99mTc-MIBI en el diagnóstico y seguimiento de los linfomas Hodgkin y no Hodgkin. Rev Esp Med Nuclear. 2000;( 19): 85-91.
13. American Cancer Society. Cancer Statistic 1996. Professional Publication: CA-A Jond for Clinicians. CA 46. 1996: 5-27.
14. SONG HC, LEE JJ, BOM HS, CHENG IJ, KIM HJ, PARK YK, KIM EE. Double-phase Tc-99m MIBI scintigraphy as a therapeutic predictor in patients with non-Hodgkin’s lymphoma. Clin. Nucl. Med. 2003; 28 ( 6): 457-462.
15. LIANG JA, SHIAU YC, YANG SN, LIN FJ, KAO A, LEE CC. Prediction of chemotherapy response in untreated malignant lymphomas using technetium-99m methoxyisobutylisonitrile scan: comparison with P-glycoprotein expression and other prognostic factors; A preliminary report. Jpn J Clin Oncol. 2002; 32 ( 4): 140-145.
16. KAO CH, TSAI SC, WANG JJ, HO YJ, HO ST, CHANGLAI SP. Evaluation of chemotherapy response using technetium-99M-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report. Int J Cancer. 2001; 95 ( 4): 228-231.
17. TSAI SC, SHIAU YC, WANG JJ, HO YJ, KAO CH. Comparison of the uptake and clearance of Tc-99m MIBI, Tl-201 and Ga-67 in drug-resistant lymphoma cell lines. Cancer Lett. Oct 0. 2001; 71 ( 2): 147-152.
18. KABASAKAL L, OZKER K, HAYWARD M, AKANSEL G, GRIFITH O, ISITMAN AT, col. Technetium-99msestamibi uptake in human breast carcinoma cell lines displaying glutathione associated drug-resistance. Eur J Nucl Med. 1996;( 23): 568-70.
2. PAREDES A, BLANCO C, ECHENIQUE M. Expresión de proteínas relacionadas con resistencia a múltiples drogas (MDR-Proteínas) en el cáncer de pulmón. Oncología. 2005; 28 ( 8): 378-393.
3. BAE KT, PIWNICA WORMS D. Pharmacokinetics modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates. Q J Nucl Med. 1997;( 41): 101-108.
4. CHIU M, KRONAUGE J, PIWNICA-WORMS D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxy-isobutyl-isonitrile) technetium I in cultured mouse fibroblasts. J Nucl Med. 1990;( 31): 1646-1653.
5. OZLEM KL, AKYUZ C, VURAL G, OGUZ A, ATASEUER T. BUYUKPAMUKCU, Evaluation of therapy response in children with untreated malignant lymphomas using Tc-99m-sestamibi. J Nucl Med. 1997;( 38): 243-247.
6. PROULX A, BALLINGER JR, GULENCHYN KY. Routine determination of radiochemical purity of (99m)Tc-MIBI. Appl Radiat Isot. 1989;( 40): 95-97.
7. LEE NS, JAFFE E, STEIN H, BANKS P, CHAN J, CLEARY M, et al. A revised European-American classification of lymphoid neoplasm: A proposal from the international lymphoma study group. Blood. 1994;( 84): 1361-1392.
8. KOMOTO D, NISHIYAMA Y, YAMAMOTO Y, MONDEN T, SASAKAWA Y, TOYAMA Y, SATOH K, OHNO M, KANENISHI K, OHKAWAM. A case of non-hodgkin’s lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response. Ann Nucl Med. 2006; 20 ( 2): 157-160.
9. ZIJLSTRA JM, LINDAUER-VAN-DER-WERF G, HOEKSTRA OS, HOOFT L, RIPHAGEN II, HUIJGENS PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica. 2006; 91 ( 4): 522-529.
10. RICART Y. La gammagrafía con citrato de 67Ga en el estudio de los linfomas. Rev Esp Med Nuclear. 2002;( 21): 85-87.
11. LIN PC, CHUN J, POCOCK N. 18F Fluorodeoxyglucose imaging with coincidence dual-head gamma camera (hybrid-PET) for staging of lymphoma: comparison with Ga-67 scintigraphy. J Nucl Med. 2000;( 41) (suppl): 118.
12. SOLANO BRAVO ME, PERERA PINTADO A, GÓMEZ PÉREZ JR, RODRÍGUEZ JL, SÁNCHEZ MENDOZA EL, PÉREZ VALDÉS M, SÁNCHEZ-DEL-CAMPO-ROMERO MP. Valor de la gammagrafía con 99mTc-MIBI en el diagnóstico y seguimiento de los linfomas Hodgkin y no Hodgkin. Rev Esp Med Nuclear. 2000;( 19): 85-91.
13. American Cancer Society. Cancer Statistic 1996. Professional Publication: CA-A Jond for Clinicians. CA 46. 1996: 5-27.
14. SONG HC, LEE JJ, BOM HS, CHENG IJ, KIM HJ, PARK YK, KIM EE. Double-phase Tc-99m MIBI scintigraphy as a therapeutic predictor in patients with non-Hodgkin’s lymphoma. Clin. Nucl. Med. 2003; 28 ( 6): 457-462.
15. LIANG JA, SHIAU YC, YANG SN, LIN FJ, KAO A, LEE CC. Prediction of chemotherapy response in untreated malignant lymphomas using technetium-99m methoxyisobutylisonitrile scan: comparison with P-glycoprotein expression and other prognostic factors; A preliminary report. Jpn J Clin Oncol. 2002; 32 ( 4): 140-145.
16. KAO CH, TSAI SC, WANG JJ, HO YJ, HO ST, CHANGLAI SP. Evaluation of chemotherapy response using technetium-99M-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report. Int J Cancer. 2001; 95 ( 4): 228-231.
17. TSAI SC, SHIAU YC, WANG JJ, HO YJ, KAO CH. Comparison of the uptake and clearance of Tc-99m MIBI, Tl-201 and Ga-67 in drug-resistant lymphoma cell lines. Cancer Lett. Oct 0. 2001; 71 ( 2): 147-152.
18. KABASAKAL L, OZKER K, HAYWARD M, AKANSEL G, GRIFITH O, ISITMAN AT, col. Technetium-99msestamibi uptake in human breast carcinoma cell lines displaying glutathione associated drug-resistance. Eur J Nucl Med. 1996;( 23): 568-70.